临床医学工程2024，Vol.31Issue(11)：1329-1330,2.DOI:10.3969/j.issn.1674-4659.2024.11.1329
碳酸司维拉姆联合血液灌流和血液透析治疗CKD-MBD的有效性及安全性探讨
Exploration on the Efficacy and Safety of Sevelamer Carbonate Combined with Hemoperfusion and Hemodialysis in the Treatment of CKD-MBD
凌宇凤 1简建业 1吕志云1
作者信息
- 1. 吴川市人民医院肾病内科,广东吴川 524500
- 折叠
摘要
Abstract
Objective To explore the efficacy and safety of sevelamer carbonate combined with hemoperfusion(HP)and hemodialysis(HD)in the treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD).Methods 80 patients with CKD-MBD in our hospital from October 2022 to October 2023 were randomly divided into two groups.The control group was treated with HP and HD,and the observation group was treated with sevelamer carbonate combined with HP and HD.The calcium and phosphorus metabolism,renal function and adverse reactions were compared between the two groups.Results After 3 months of treatment,the blood phosphorus of the observation group was lower than that of the control group,and the blood calcium was higher than that of the control group(P<0.05).After 3 months of treatment,the blood urea nitrogen,uric acid,and serum creatinine of the observation group were lower than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Sevelamer carbonate combined with HP and HD has significant effect in the treatment of CKD-MBD,and has similar safety comparable to traditional HP and HD treatment.关键词
慢性肾脏病-矿物质和骨代谢异常/碳酸司维拉姆/血液灌流/血液透析Key words
Chronic kidney disease-mineral and bone disorder/Sevelamer carbonate/Hemoperfusion/Hemodialysis分类
医药卫生引用本文复制引用
凌宇凤,简建业,吕志云..碳酸司维拉姆联合血液灌流和血液透析治疗CKD-MBD的有效性及安全性探讨[J].临床医学工程,2024,31(11):1329-1330,2.
